jeudi 4 juin 2009

Novavax en proie à de graves difficultés financières voit son action augmenter de 529% depuis avril avec l'annonce d'un vaccin contre la grippe H1N1

Novavax surges on swine flu vaccine
Thursday, June 4, 2009, 12:16pm EDT
Washington Business Journal - by Jeff Clabaugh Staff Reporter

Novavax stock surged nearly 50 percent Thursday after the Rockville company said it had succeeded in producing a swine flu vaccine and the government has agreed to test it.

Novavax, which began working on a vaccine for the N1H1 virus earlier this year, says it produced the first batch of the vaccine in May. Novavax uses a technology that greatly speeds the time it takes to make vaccines. It says it has now completed the genetic engineering and manufacture of the stock needed to mass produce the virus.

As a result, Novavax and the National Institutes of Health’s National Institute of Allergy and Infectious Diseases have signed an agreement that will let government scientists evaluate the vaccine.

“The company has committed necessary resources to respond as rapidly as possible to construct and manufacture VLP vaccine against this new N1H1 influenza virus,” said Novavax CEO Rahul Singhvi in a statement.

Novavax has the capacity to produce large amounts the vaccine at its manufacturing facilities in Rockville.

Novavax stock (NASDAQ: NVAX) was up 88 cents to $2.75 per share in afternoon trading. Its stock was trading as low as 52 cents per share in early April.

Aucun commentaire:

Enregistrer un commentaire